CPC Class C12Q

The present invention provides an inbred corn line designated GAQ2004, methods for producing a corn plant by crossing plants of the inbred line GAQ2004 with plants of another corn plant. The invention further encompasses all parts of inbred corn line GAQ2004, including culturable cells. Additionally provided herein are methods for introducing transgenes into inbred corn line GAQ2004, and plants produced according to these methods.

The present invention relates to a Lactuca sativa seed designated 41-149 RZ, which exhibits a combination of traits including resistance to downy mildew (Bremia lactucae) races Bl:1 to Bl:26, Bl:28, Bl:32, and Ca-I to Ca-VIII, resistance to corky root rot (Sphingomonas suberifaciens), and resistance to currant-lettuce aphid (Nasonovia ribisnigri) biotype Nr:0, as well as having a reduced wound-induced surface discoloration, leaves with a solid main vein and broad base leaves. The present invention also relates to a Lactuca sativa plant produced by growing the 41-149 RZ seed. The invention further relates to methods for producing the lettuce cultivar, represented by lettuce variety 41-149 RZ.

Methods are disclosed for non-invasively obtaining fetal cells from a pregnant female. The methods include placing an absorbent medium in an interlabial or intravaginal space or adjacent to the perineum at the vaginal opening of the pregnant female, and collecting vaginal fluid comprising cells in the absorbent medium while the absorbent medium is interlabial or intravaginal space or adjacent to the perineum at the vaginal opening. The absorbent medium is removed and cells are isolated from the absorbent medium to obtain the fetal cells. The fetal cells can be, for example, somatic cells, embroyic stem cells, fetal stem cells or trophoblast cells.

Described herein are methods of treating an Acanthamoeba infection in a subject in need thereof by administering an amount of apocynin.

A method for treating a prokaryotic infection in an animal or human by administering a pharmaceutically acceptable composition, comprising administering a source of silver ions and a benzoisoselenazol derivative, e.g., an ebselen derivative.

Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.